Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Novo Nordisk expands social media efforts with new Twitter account

Danish pharma company's US business joins the social network

Novo Nordisk US Twitter account

Novo Nordisk has expanded its social media efforts, launching a new Twitter account for its US business.

It joins the Danish pharma company's existing accounts on the social network, which focus on corporate sustainability, graduate recruitment, and government affairs and public policy.

Its most note-worthy US social media initiative to date has been its sponsorship of Race with Insulin, which is pharma's first – and, so far, only – branded Twitter account.

Run by Indy car driver, and Novo-paid spokesman, Charlie Kimball, who has type I diabetes, the Twitter account's background currently features branding for the NovoLog Flexpen.

Novo's new Twitter account will be run by its US media relations and corporate communications director Ken Inchausti and focus on “news and views on diabetes and chronic disease for US audiences”.

• Links to Novo's new Twitter account and its existing social media initiatives can be found in the Digital Handbook's pharma social media directory

30th April 2012

From: Marketing


Featured jobs

Subscribe to our email news alerts


Add my company

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...